XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
  X Chromosome
  Genetic Disorders
  Cloning
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Genetics Channel
subscribe to Genetics newsletter

Latest Research : Genetics

   DISCUSS   |   EMAIL   |   PRINT
Japanese haplotypes would help in identifying genes associated with disease and drug response
Oct 29, 2005, 16:29, Reviewed by: Dr.

�Understanding the patterns of genetic variation in the Japanese population will greatly enhance our ability to identify genes associated with disease and drug response."

 
Researchers at Kyushu University of Japan, in collaboration with Perlegen Sciences, Inc., have identified common patterns of human DNA sequence variation, or haplotypes, in the Japanese population. By combining a unique set of DNA samples collected at the Medical Institute of Bioregulation at Kyushu University with Perlegen�s high throughput, whole-genome analysis approach, based on next generation Affymetrix GeneChip � technology, the collaborators identified common haplotypes that can be used to conduct comprehensive genetic research on human disease and variable response to medicines.

�Understanding the patterns of genetic variation in the Japanese population will greatly enhance our ability to identify genes associated with disease and drug response� stated Dr. Kenshi Hayashi, Professor of the Research Center for Genetic Information, Medical Institute of Bioregulation at Kyushu University. �The unique approach of this study complements the recently completed International HapMap project. Both studies make critical contributions to enabling personalized medicine in Japan.�

The collaboration between Kyushu University and Perlegen Sciences was particularly effective in identifying long-range haplotypes (over one million bases long). �With this study, Dr. Hayashi and his colleagues at Kyushu University have made an important contribution to medical research in Japan,� stated David Cox, Chief Scientific Officer of Perlegen. �It will enable researchers to identify the genetic factors that determine why drugs work well for some patients, but not for others.�

"Collaborating with the top researchers in Japan such as Dr. Hayashi is a priority for Perlegen,� stated Akira Usui, General Manager of Perlegen Japan, KK. �We are committed to improving the therapeutic treatments available to Japanese patients.�

Kyushu University and Perlegen Sciences will report their findings in the October 26 issue of Genome Research.
 

- Kyushu University
 

www.perlegen.com

 
Subscribe to Genetics Newsletter
E-mail Address:

 

About Kyushu University

Founded in 1903 as the Fukuoka Medical College, Kyushu University is one of the leading universities in Japan, with over 16,000 students, over 2,000 faculty and over 6,000 researchers in a variety of schools, institutes and hospitals. The Research Center for Genetic Information, founded in 1993, is part of Kyushu University�s Medical Institute of Bioregulation. The center focuses on developing DNA analytical technologies and investigating genetic factors for hereditary diseases.

Contact

Dr. Kenshi Hayashi

Director, Division of Genome Analysis

Research Center for Genetic Information

Medical Institute of Bioregulation

Kyushu University

[email protected]

About Perlegen Sciences

Perlegen Sciences, Inc. and Perlegen Sciences Japan, K.K. are working to provide safe and effective medicines to the world. The companies quickly and cost effectively analyzes millions of genetic variations in DNA samples obtained from clinical trial participants. This information is used to explain and predict the efficacy and adverse effect profiles of prescription drugs. Perlegen also applies this expertise to discovering genetic variants associated with disease for potential new therapeutics and diagnostics. For years, scientists and drug manufacturers have been eager to comprehensively examine entire genomes; through Perlegen, this is now possible. Perlegen is able to bring drugs to the market that may otherwise have been discontinued in clinical development.

Based in Mountain View, California, Perlegen Sciences was formed in late 2000 as a spin-off from Affymetrix, Inc. (Nasdaq: AFFX). For more information about the company and its technologies, visit Perlegen's website at www.perlegen.com. Perlegen Sciences, Perlegen, and the Perlegen logo are trademarks of Perlegen Sciences, Inc.

Contacts

Perlegen Sciences, Inc.
Paul Cusenza
Senior Vice President
(650) 625-4500

Perlegen Sciences Japan, KK

Akira Usui

Representative Director & General Manager

+81 (0)3 3444-6080


Related Genetics News

New research into csd genes could help designing strategies for breeding honey bees
Williams Syndrome, the brain and music
Genetic mutation identified as cause of cranio-lenticulo-sutural dysplasia
Chance Fluctuations in mRNA Output in Mammalian Cells
Transposon Silencing Keeps Jumping Genes in Their Place
GATA2 - predicting susceptibility to coronary artery disease
Exploring genetics of congenital malformations
Genome insertions and deletions (INDELs) provide expanded view of human genetic differences
BRIT1 gene identified as protector of DNA
FDA Approves Idursulfase As First Treatment for Hunter Syndrome


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us